• Facebook
  • Twitter
  • LinkedIn
  • Google +
  • RSS

Norbert Bischofberger - Articles and news items

Gilead logo

Gilead to stop Phase 3 Study 116 of Idelalisib in chronic lymphocytic leukemia early because of positive risk benefit

Industry news / 9 October 2013 / Gilead

“We are pleased that idelalisib has shown a clinically meaningful benefit for patients…”

Gilead logo

Gilead reports interim data from Phase 2 LONESTAR study

Industry news, News / 2 May 2013 / Gilead Sciences

Gilead Sciences announced plans to initiate a third Phase 3 clinical trial…

Gilead logo
Gilead logo

Gilead’s sofosbuvir for hepatitis C meets primary endpoint in fourth pivotal Phase 3 study

Industry news, News / 19 February 2013 / Gilead Sciences

Topline results from the Phase 3 FUSION study…

Gilead logo

Gilead announces sustained virologic response rates from two Phase 3 studies of sofosbuvir for hepatitis C

Industry news, News / 4 February 2013 / Gilead Sciences, Inc.

Topline results from two Phase 3 studies…

Gilead logo

Gilead initiates Phase 3 clinical program for tenofovir alafenamide

Industry news, News / 24 January 2013 / Gilead Sciences

“We are pleased to move TAF into Phase 3 clinical research…”

Gilead logo

Gilead provides update on Hepatitis C development programs

Industry news, News / 7 January 2013 / Gilead Sciences

Gilead Sciences announced several updates regarding its late-stage pipeline candidates for the treatment of chronic HCV infection…

Gilead logo

Gilead Sciences to acquire YM BioSciences

Industry news, News / 12 December 2012 / Gilead Sciences

Gilead Sciences and YM BioSciences announced that the companies have signed a definitive agreement…

Gilead logo

European Commission approves Viread®

Industry news, News / 27 November 2012 / Gilead Sciences, Inc.

Gilead Sciences announced that the European Commission has granted marketing authorization for two new indications for once-daily Viread®…

Gilead logo

Gilead announces sustained virologic response rate of 78% from Phase 3 study of sofosbuvir for genotype 2/3 hepatitis C infected patients

Industry news, News / 27 November 2012 / Gilead Sciences

Gilead Sciences announced topline results from the Phase 3 POSITRON study…

Gilead logo

Gilead’s once-daily novel prodrug for the treatment of HIV meets 24-week primary objective in Phase 2 study

Industry news, News / 31 October 2012 / Gilead Sciences

Data support tenofovir alafenamide fumarate as component of future single tablet HIV regimens…

Gilead logo

Gilead ’s Boosting Agent Cobicistat for HIV Therapy as Effective as Ritonavir in Pivotal Phase 3 Study

News / 24 July 2012 / Gilead Sciences, Inc.

Full clinical trial results from a pivotal Phase 3 study…

 

Webinar: Use of MicroNIR to optimise fluid bed drying and to reduce waste at tablet compressionFIND OUT MORE
+ +